Lonneke de Boer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Lonneke de Boer has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Albena Jordanova
VIB-UAntwerp Center for Molecular Neurology: Antwerp, Belgium; Medical univercity - Sofia
1 shared publication - Alzira Alves de Siqueira Carvalho
Neurosciences and Clinical Department, Centro Universitário ABC, Santo André, Brazil
1 shared publication - Anita Cairns
Neurosciences Department Queensland Children's Hospital Brisbane Queensland Australia
1 shared publication - Annemarie de Vreugd
United for Metabolic Diseases (UMD) Netherlands
1 shared publication - Ayse Candayan
Molecular Neurogenomics Group, VIB Center for Molecular Neurology, VIB Antwerp Belgium
1 shared publication Benno Kusters
1 shared publication
Latest Publications
- Open Access
- 20 August 2026
- Published by Elsevier in SSRN Electronic Journal
Clinical, molecular, and cardiac characterization of four rare mtDNA variants affecting mt-tRNA genes in pediatric mitochondrial disease
IntroductionMitochondrial diseases (MD) are genetically heterogeneous disorders caused by impaired oxidative phosphorylation (OXPHOS). Pathogenic variants in mitochondrial DNA (mtDNA) genes encoding mitochondrial transfer RNAs (mt-tRNAs) represent a significant subgroup, yet many rare variants remain poorly characterized. Cardiac involvement is recognized but may be subclinical and underdetected. This study aimed to characterize and expand the clinical, molecular, and biochemical phenotype of four rare mtDNA variants (m.4300A>G, m.4404T>C, m.7507A>G, and m.608A>G) through detailed phenotyping. In addition, we assessed cardiac involvement with electrocardiography and speckle-tracking echocardiography. MethodsWe conducted a retrospective case series of four pediatric patients at a national mitochondrial expertise center. Clinical, genetic, biochemical, and histological data were collected. Cardiac evaluation included electrocardiography, conventional echocardiography, and two-dimensional speckle-tracking strain imaging. A targeted literature review was performed for all variants. ResultsDisease onset occurred in early childhood, with phenotypes ranging from isolated mitochondrial myopathy to progressive multisystem encephalomyopathy. Cardiac symptoms were absent or mild. Mild ECG abnormalities were consistently present, including QRS fragmentation, repolarization changes, and microvoltages. Conventional echocardiography was normal in all patients. Speckle-tracking echocardiography was abnormal in two patients: one showed mildly reduced global longitudinal strain, whereas another showed regional wall-motion abnormalities despite preserved global strain. The m.4404T>C variant is reported for the first time, and the other variants extend beyond previously described organ-specific presentations. ConclusionRare mtDNA variants affecting mt-tRNA genes show marked phenotypic heterogeneity and may include subclinical cardiac abnormalities despite normal conventional echocardiography. Speckle-tracking echocardiography may add value to longitudinal cardiac phenotyping in pediatric mitochondrial disease.
- 20 August 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessClinical, molecular, and cardiac characterization of four rare mtDNA variants affecting mt-tRNA genes in pediatric mitochondrial disease
IntroductionMitochondrial diseases (MD) are genetically heterogeneous disorders caused by impaired oxidative phosphorylation (OXPHOS). Pathogenic variants in mitochondrial DNA (mtDNA) genes encoding mitochondrial transfer RNAs (mt-tRNAs) represent a significant subgroup, yet many rare variants remain poorly characterized. Cardiac involvement is recognized but may be subclinical and underdetected. This study aimed to characterize and expand the clinical, molecular, and biochemical phenotype of four rare mtDNA variants (m.4300A>G, m.4404T>C, m.7507A>G, and m.608A>G) through detailed phenotyping. In addition, we assessed cardiac involvement with electrocardiography and speckle-tracking echocardiography. MethodsWe conducted a retrospective case series of four pediatric patients at a national mitochondrial expertise center. Clinical, genetic, biochemical, and histological data were collected. Cardiac evaluation included electrocardiography, conventional echocardiography, and two-dimensional speckle-tracking strain imaging. A targeted literature review was performed for all variants. ResultsDisease onset occurred in early childhood, with phenotypes ranging from isolated mitochondrial myopathy to progressive multisystem encephalomyopathy. Cardiac symptoms were absent or mild. Mild ECG abnormalities were consistently present, including QRS fragmentation, repolarization changes, and microvoltages. Conventional echocardiography was normal in all patients. Speckle-tracking echocardiography was abnormal in two patients: one showed mildly reduced global longitudinal strain, whereas another showed regional wall-motion abnormalities despite preserved global strain. The m.4404T>C variant is reported for the first time, and the other variants extend beyond previously described organ-specific presentations. ConclusionRare mtDNA variants affecting mt-tRNA genes show marked phenotypic heterogeneity and may include subclinical cardiac abnormalities despite normal conventional echocardiography. Speckle-tracking echocardiography may add value to longitudinal cardiac phenotyping in pediatric mitochondrial disease.
- Open Access
- 8 June 2026
- Published by Wiley in Annals of Neurology
- Vol. 100 (3) , 655-671
Monoallelic POLR3A Variants Cause Early‐Onset Peripheral Neuropathy
Objective: Biallelic variants in genes encoding the RNA polymerase III complex (Pol III) cause a spectrum of neurological disorders primarily affecting the central nervous system. Monoallelic variants have been reported in the POLR3B subunit only, associated with neurodevelopmental disorder, epilepsy, and peripheral neuropathy. We describe a novel Pol III‐related disorder caused by monoallelic variants in POLR3A and presenting primarily with peripheral neuropathy. Methods: We performed clinical and genetic investigation of the affected families. Biophysical characterization of mutant proteins was performed in silico. Immunoblotting, interactomics, and transcriptomics characterization were done in cellular models. Results: We identified 11 patients across 8 unrelated families harboring heterozygous missense variants in POLR3A, occurring de novo or segregating in an autosomal‐dominant fashion. The patients presented with an early‐onset, progressive sensorimotor peripheral polyneuropathy with intermediate to demyelinating ranges of nerve conduction slowing, occasionally accompanied with neurological or non‐neurological features. White matter abnormalities, characteristic for the biallelic Pol III‐related disorders, where not observed in the brain magnetic resonance imaging (MRI) evaluations. The neuropathy‐associated variants cluster in regions critical for Pol III activity. We observed mis‐regulation of individual Pol III targets and global downregulation of tRNA pools in patient‐derived cells. This Pol III dysfunction was not due to impaired POLR3A expression, subcellular localization, or subunit interactions. Interpretation: Our findings expand the Pol III‐related disease spectrum beyond the known biallelic phenotypes and establish POLR3A as a novel peripheral neuropathy‐associated gene. This work highlights a central role of Pol III dysfunction in disease and reinforces the link between tRNA metabolism and peripheral neurodegeneration. ANN NEUROL 2026
- 8 June 2026
- Published by Wiley in Annals of Neurology
- Vol. 100 (3) , 655-671
Open AccessMonoallelic POLR3A Variants Cause Early‐Onset Peripheral Neuropathy
Objective: Biallelic variants in genes encoding the RNA polymerase III complex (Pol III) cause a spectrum of neurological disorders primarily affecting the central nervous system. Monoallelic variants have been reported in the POLR3B subunit only, associated with neurodevelopmental disorder, epilepsy, and peripheral neuropathy. We describe a novel Pol III‐related disorder caused by monoallelic variants in POLR3A and presenting primarily with peripheral neuropathy. Methods: We performed clinical and genetic investigation of the affected families. Biophysical characterization of mutant proteins was performed in silico. Immunoblotting, interactomics, and transcriptomics characterization were done in cellular models. Results: We identified 11 patients across 8 unrelated families harboring heterozygous missense variants in POLR3A, occurring de novo or segregating in an autosomal‐dominant fashion. The patients presented with an early‐onset, progressive sensorimotor peripheral polyneuropathy with intermediate to demyelinating ranges of nerve conduction slowing, occasionally accompanied with neurological or non‐neurological features. White matter abnormalities, characteristic for the biallelic Pol III‐related disorders, where not observed in the brain magnetic resonance imaging (MRI) evaluations. The neuropathy‐associated variants cluster in regions critical for Pol III activity. We observed mis‐regulation of individual Pol III targets and global downregulation of tRNA pools in patient‐derived cells. This Pol III dysfunction was not due to impaired POLR3A expression, subcellular localization, or subunit interactions. Interpretation: Our findings expand the Pol III‐related disease spectrum beyond the known biallelic phenotypes and establish POLR3A as a novel peripheral neuropathy‐associated gene. This work highlights a central role of Pol III dysfunction in disease and reinforces the link between tRNA metabolism and peripheral neurodegeneration. ANN NEUROL 2026